Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085390 | 1.00 | HRH3 (0.40) | HRH3SLC6A4CMKLR1CHEK1HRH2 | |
| SCHEMBL3950058 | 1.00 | HRH3 (0.40) | HRH3SLC6A4CMKLR1CHEK1HRH2 | |
| SCHEMBL4085007 | 1.00 | HRH3 (0.40) | HRH3SLC6A4CMKLR1CHEK1HRH2 | |
| SCHEMBL4094449 | 0.91 | CHRNB1 (0.43) | — | |
| SCHEMBL4186038 | 0.91 | CHRNB1 (0.43) | — | |
| SCHEMBL4084896 | 0.91 | CHRNB1 (0.43) | — | |
| SCHEMBL4089143 | 0.89 | CHRNB1 (0.41) | SLC6A4 | |
| SCHEMBL4079746 | 0.88 | MCHR1 (0.37) | HRH3 | |
| SCHEMBL4079745 | 0.88 | MCHR1 (0.37) | HRH3 | |
| SCHEMBL4080211 | 0.86 | SLC6A2 (0.36) | HRH3SLC6A4CMKLR1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791831-A4 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARM LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1791831-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | Signal Pharmaceuticals LLC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051308-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050107386-A1 | Methods of treating diseases and disorders by targeting multiple kinases | NARLA RAMA KRISHNA (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107386-A1 | Methods of treating diseases and disorders by targeting multiple kinases | MAP3K20, MAP3K2, MAP3K1 | HRH3 2868/4885SLC6A4 4637/4885CMKLR1 3142/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | HRH3 2504/4885SLC6A4 2787/4885CMKLR1 1073/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | HRH3 2769/4885SLC6A4 2832/4885CMKLR1 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.